Leukemia-Lymphoma

Game-changing gene therapies present cost problems for health execsCAR-T therapies have high price tags so it’s important to understand your patient population and budget impact.
Four ways health execs can prep for costly CAR-T cell therapiesWith the high efficacy and dire diagnosis, there will be demand for both Kymriah and Yescarta. Here’s how to manage the monetary impact.
This is why you should be excited for upcoming cancer researchAcute myeloid leukemia experts share promising new developments on the oncology horizon.
Four things payers need to know about acute myeloid leukemiaPhysicians need to be able to move quickly to care for patients with AML, and they need to have payers on board.
Rapid oncology innovation raises management challenges for payersOncology is a complex and rapidly-evolving management challenge for payers.
Six diseases reap benefits of biomarkers, genetic tests
Six diseases reap benefits of biomarkers, genetic testsBiomarker testing for harmful genetic mutations provides the opportunity to identify at-risk individuals who might benefit from risk modification strategies and/or enhanced disease screening.
Family history, genetics play growing role in leukemia screeningInherited susceptibilities to leukemias are becoming better understood and have important implications for screening, prevention, genetic counseling, and treatment.
Promising treatment developments in lymphoma immunotherapiesIn this Q&A, a physician and lymphoma expert discusses treatment advances and promising signs for the future.
Novel immunotherapies for leukemia could raise life-threatening syndromeNovel immunotherapy treatments are showing promise for patients with acute lymphoblastic leukemia (ALL), but they can trigger cytokine release syndrome.
Hodgkin lymphoma: First hematologic cancer cured with immunotherapy?Immune checkpoint inhibitors are taking the stage in treating relapsed and refractory Hodgkin lymphoma. Read more.